Biosimilar debate focuses on key lawmaker

Palo Alto Democrat Rep. Anna Eshoo has been a key sponsor of the bill backing 12 years of data exclusivity for biologics, a position dearly loved by the 2,000 biomedical companies in California. But her position that the bill is a boon for consumers, establishing a pathway for biosimilar approvals that doesn't currently exist, has come under fierce attack from a variety of analysts who say Eshoo is simply helping to ensure that biologic prices remain sky high. Report

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.